Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome

References

• Jaffe E. Classification of natural killer cell and NK-like T-cell malignancies. Blood 1996; 87: 1207–1210
   PubMed Web of Science ®Google Scholar
• Suzuki R, Nakamura S. Malignancies of natural killer cell precursor: myeloid/NK cell precursor acute leukemias and blastic NK cell lymphoma/leukemia. Leuk Res 1999; 23: 615–624
   PubMed Web of Science ®Google Scholar
• Inaba T, Shimazaki C, Sumikuma T, Ochiai N, Okano A, Hatsuse M, et al. Clinicopathological features of myeloid/natural killer cell precursor acute leukemia. Leuk Res 2001; 25: 109–113
   PubMed Web of Science ®Google Scholar
• Rakozy Ch, Mohamed A, Vo T, Khatib G, Long M, Eilender D, et al. CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically, cytogenetically, and clinically diverse. Am J Clin Pathol 2001; 116: 168–176
   PubMed Web of Science ®Google Scholar
• Drexler H, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 2000; 14: 777–782
   PubMed Web of Science ®Google Scholar
• Kameoka J, Ichinohasama R, Tanaka M, Miura I, Tomiya Y, Takahashi S, et al. A cutaneous agranular CD2− CD4+ CD56+ ‘lymphoma’. Report of two cases and review of the literature. Hematopathology 1998; 110: 478–488
   Google Scholar
• Shinoda K, Muraki T, Yano M, Yamada T, Takao A. Infant leukemia suggestive of natural killer cell precursor origin followed an unusual clinical course. Acta Haematol 2000; 104: 202–206
   PubMed Web of Science ®Google Scholar
• Gattei V, Carbone A, Zagonel V, Pinto A. Expression of natural killer antigens in a subset of non-T non-B lymphoma/leukemia with histiocytic features. Br J Haematol 1990; 76: 443–446
   Web of Science ®Google Scholar
• Jaffe E, Harris N, Stein H, Vardiman J. WHO Classification: Pathology and Genetics of Tumors of the Haemopoietic and Lymphoid Tissues. IARC Press, Lyon 2001; 106–107
   Google Scholar
• Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001; 97: 3210–3217
   PubMed Web of Science ®Google Scholar
• Penna G, Vulcano M, Sozzan S, Adorini L. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Hum Immunol 2002; 63: 1164–1171
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Liu Y. Natural type I interferon-producing cells as a link between innate and adaptive immunity. Hum Immunol 2002; 63: 1126–1132
   PubMed Web of Science ®Google Scholar
• Ito T, Amakawa R, Fukuhara S. Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. Hum Immunol 2002; 63: 1120–1125
   PubMed Web of Science ®Google Scholar
• Dzionek A, Inagaki Y, Okawa K, Nagafune J, Rock J J, Sohma Y, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol 2002; 63: 1133–1148
   PubMed Web of Science ®Google Scholar
• Blom B, Ligthart S, Schotte R, Spits H. Developmental origin of Pre-DC2. Hum Immunol 2002; 63: 1072–1080
   PubMed Web of Science ®Google Scholar
• Brière F, Bendriss-Vermare N, Delale T, Burg S, Corbet Ch, Rissoan M C, et al. Origin and filiation of human plasmacytoid dendritic cells. Hum Immunol 2002; 63: 1081–1093
   PubMed Web of Science ®Google Scholar
• Lipscomb M, Masten B. Dendritic cells: immune regulators in health and disease. Physiol Rev 2002; 82: 97–124
   PubMed Web of Science ®Google Scholar
• Olweus J, Bit Mansour A, Warnke R, Thompson P A, Carballido J, Picker L J, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 1997; 94: 12551–12556
   PubMed Web of Science ®Google Scholar
• Mc Donald K P, Munster D J, Clark G J, Dzionek A, Schmitz J, Hart D N. Characterization of human blood dendritic cells. Blood 2002; 100: 4512–4520
   PubMed Web of Science ®Google Scholar
• Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 127: 6037–6046
   Google Scholar
• Feuillard J, Jacob M, Valensi F, Maynadie M, Gressin R, Chaperot L, et al. Clinical and biological features of CD4+ CD56+ malignancies. Blood 2002; 99: 1556–1562
   PubMed Web of Science ®Google Scholar
• Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J, et al. CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. Blood 2002; 99: 4154–4159
   PubMed Web of Science ®Google Scholar
• Jacob M C, Chaperot L, Mossuz P, Feuillard J, Valensi F, Leroux D, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 2003; 88: 941–955
   PubMed Web of Science ®Google Scholar
• Ribas A, Bernasconi A, Felice M S, Somardzic A, Gallego M, Rossi J. Leucemia linfoblástica aguda de precursor de células dendríticas/NK en pediatría: un entidad diferente. Hematología 2001; 5: 148
   Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Swirsky D, Bain B J. Erythrocyte and leucocyte cytochemistry-leukaemia classification. Practical Haematology9th edn., S M Lewis, B J Bain, I Bates. Harcourt Publishers Limited, London 2001; 269–296
   Google Scholar
• Williams D L, Harris A, Williams K J, Brosius M J, Lemonds W. A direct bone marrow chromosome technique of acute lymphoblastic leukemia. Cancer Genet Cytogenet 1984; 13: 239–257
   PubMed Web of Science ®Google Scholar
• Mitelman F. ISCN. An International System for Human Cytogenetic Nomenclature. Karger, ES Basel 1995
   Google Scholar
• Diss T C, Watts M, Pan L X, Burke M, Linch D, Isaacson P G. The polymerase chain reaction in the demonstration of monoclonality in T cell lymphomas. J Clin Pathol 1995; 48: 1045–1050
   PubMed Web of Science ®Google Scholar
• Sackmann-Muriel F, Felice M, Zubizarreta P, Alfaro E, Gallego M, Rossi J. Treatment results in childhood acute lymphoblastic leukemia with a modified ALL-BFM'90 protocol: lack of improvement in high-risk group. Leuk Res 1999; 23: 331–340
   PubMed Web of Science ®Google Scholar
• Felice M S, Alfaro E, Rossi J, Gallego M, Fraquelli L, Latella A, et al. No benefit of a rotational continuation phase in acute lymphoblastic leukemia (ALL) with a BFM back-bone therapy: report from a single Institution. Fourth Biennial Hannover Symposium on Childhood Leukemia. CelleGermany 2004, Abstract Book
   Google Scholar
• Petrella T, Comeau M, Maynadié M, Couillault G, De Muret A, Maliszewski C R, et al. Agranular CD4+ CD56+ hematodermic neoplasm (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26: 852–862
   PubMed Web of Science ®Google Scholar
• Trimoreau F, Donnard M, Turlure P, Gachard N, Bordessoule D, Feuillard J. The CD4+ CD56+ CD116− CD123+ CD45RA+ CD45RO− profile is specific of DC2 malignancies. Haematologica 2003; 88, ELT10
   PubMedGoogle Scholar
• Res P CM, Couwenberg F, Vyth-Dreese F A, Spits H. Expression of pTa mRNA in a committed dendritic cell precursor in the human thymus. Blood 1999; 94: 2647–2657
   PubMed Web of Science ®Google Scholar
• Schotte R, Rissoan M C, Bendriss-Vermare N, Bridon J M, Duhen T, Weijer K, et al. The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development. Blood 2003; 101: 1015–1023
   PubMed Web of Science ®Google Scholar
• Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001; 194: F59–F63
   PubMed Web of Science ®Google Scholar
• Anargyrou K, Paterakis G, Boutsis D. An unusual case of CD4+ CD7+ CD56+ acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia. Eur J Haematol 2003; 71: 294–298
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Heinsch M, Haase S, Aul C. Early plasmacytoid dendritic cell leukemia/lymphoma coexpressing myeloid antigens. Ann Hematol 2004; 83: 716–721
   PubMed Web of Science ®Google Scholar
• Bueno C, Almeida J, Lucio P, Marco J, García R, De Pablos J, et al. Incidence and characteristics of CD4/HLA DRhi dendritic cell malignancies. Haematologica 2004; 89: 58–69
   PubMed Web of Science ®Google Scholar
• Garnache-Ottou F, Chaperot L, Biichle S, Ferrand Ch, Remy-Martin J P, Deconinck E, et al. Expression of the myeloid associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood 2005; 105: 1256–1264
   PubMed Web of Science ®Google Scholar
• Almeida J, Bueno C, Alguero M C, Sanchez M L, de Santiago M, Escribano L, et al. Comparative analysis of morphological, cyotchemical, immunophenotypical and functional characteristics of normal human peripheral blood lineage CD16+/HLA-DR+/CD14−/l° cells, CD14+ monocytes and CD16− dendritic cells. Clin Immunol 2001; 100: 325–338
   PubMed Web of Science ®Google Scholar
• Hallermann C, Middel P, Griesinger F, Gunawan B, Bertsch H P, Neumann C. CD4+ CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmocytoid dendritic cells. Eur J Dermatol 2004; 14: 317–322
   PubMed Web of Science ®Google Scholar
• Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, et al. Blastic NK-cell lymphomas (agranular CD4+ CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005; 123: 662–675
   PubMed Web of Science ®Google Scholar
• Riehm H, Gardner H, Henze G, Kormhuber B, Lampert F, Niethammer D, et al. Results and significance of six randomized trials in four consecutive ALL BFM studies. Hematol Blood Transfus 1990; 33: 439–450
   PubMedGoogle Scholar
• Reiter A, Schrappe M, Ludwig W D, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of a Multicenter Trial. Blood 1994; 84: 3122–3133
   PubMed Web of Science ®Google Scholar
• Falcao R P, Garcia A B, Marques M G, Simoes B P, Fonseca B A, Rodrigues M L, et al. Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity. Leuk Res 2002; 26: 803–807
   PubMed Web of Science ®Google Scholar
• Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin. Clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995; 13: 1343–1354
   PubMed Web of Science ®Google Scholar
• Reinhardt D, Pekrun A, Lakomek M, Zimmerman M, Ritter J, Creutzig U. Primary myelosarcomas are associated with a high rate of relapse: report on 34 children from acute myeloid leukemia – Berlin–Frankfurt–Münster studies. Br J Haematol 2000; 110: 863–866
   PubMed Web of Science ®Google Scholar
• Reimer P, Rudiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, et al. What is CD4+ CD56+ malignancy and how should it be treated. Bone Marrow Transplant 2003; 32: 637–646
   PubMed Web of Science ®Google Scholar